Akorn, Inc.  

(Public, NASDAQ:AKRX)   Watch this stock  
Find more results for AKRX
36.78
-0.24 (-0.65%)
Sep 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 36.34 - 37.36
52 week 18.17 - 39.48
Open 37.22
Vol / Avg. 1.70M/1.23M
Mkt cap 3.83B
P/E 89.25
Div/yield     -
EPS 0.41
Shares 104.13M
Beta 0.32
Inst. own 84%
Dec 15, 2014
Akorn Inc at Guggenheim Healthcare Day - Life Sciences - 7:00PM EST - Add to calendar
Dec 1, 2014
Akorn, Inc. at Piper Jaffray Healthcare Conference Add to calendar
Nov 10, 2014
Akorn, Inc. at Credit Suisse Healthcare Conference Add to calendar
Nov 3, 2014
Q3 2014 Akorn Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 17, 2014
Akorn, Inc. at Morningstar's Management Behind the Moat Conference
Aug 5, 2014
Q2 2014 Akorn Inc Earnings Call - Webcast
Aug 5, 2014
Q2 2014 Akorn, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 5.98% 16.48%
Operating margin 16.74% 27.76%
EBITD margin - 33.24%
Return on average assets 4.29% 13.07%
Return on average equity 12.71% 22.70%
Employees 786 -
CDP Score - -

Address

Suite 300 1925 W. Field Court
LAKE FOREST, IL 60045
United States - Map
+1-847-2796100 (Phone)
+1-800-9433694 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Akorn, Inc. (Akom) is a manufacturer and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals, as well as niche hospital drugs and injectable pharmaceuticals. In addition, through its subsidiary Advanced Vision Research, Inc. (AVR), it manufactures and markets a line of over-the-counter (OTC) ophthalmic products for the treatment of dry eye under the TheraTears brand name, as well as a portfolio of private label OTC ophthalmic products. The Company operates in three segments: ophthalmic; hospital drugs & injectables; and contract services. In April 2014, the Company acquired Hi-Tech Pharmacal Co., Inc. In June 2014, the Company sold its subsidiary, ECR Pharmaceuticals (ECR) to Valeant Pharmaceuticals International, Inc. In August 2014, Akorn Inc. acquired VPI Holdings Corp. Effective August 12, 2014, Akorn Inc acquired VersaPharm Inc (VersaPharm).

Officers and directors

John N. Kapoor Ph.D. Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Rajat Rai Chief Executive Officer
Age: 47
Bio & Compensation  - Reuters
Timothy A. Dick Chief Financial Officer
Age: 44
Bio & Compensation  - Reuters
Bruce Kutinsky Chief Operating Officer
Age: 48
Bio & Compensation  - Reuters
Mark M. Silverberg Executive Vice President - Global Quality Assurance and Alliance Management
Age: 60
Bio & Compensation  - Reuters
Joseph P. Bonaccorsi Senior Vice President, General Counsel, Secretary
Age: 49
Bio & Compensation  - Reuters
John R. Sabat Senior Vice President - National Accounts and Trade Relations
Age: 64
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Brian Tambi Director
Age: 68
Bio & Compensation  - Reuters
Kenneth S. Abramowitz Independent Director
Age: 63
Bio & Compensation  - Reuters
Adrienne L. Graves Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters